Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Europe Antibiotics Market Size, Share & Trends Analysis Report by Drug Class (Cephalosporin, Penicillin), Type (Branded Antibodies, Generic Antibodies), Action Mechanism, Country, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
The Europe antibiotics market size is anticipated to reach USD 13.7 billion by 2030 and is projected to grow at a CAGR of 3.28% from 2024 to 2030.
The increasing urbanization and modernization result in people suffering from chronic disorders, which further drives the demand and sales of antibiotics in the region. In addition, the aged population in Europe has been demonstrated to be a primary factor driving the market growth. 
The rising infectious diseases among healthcare personnel are prevalent as a result of hospital-acquired illnesses that involve excessive antibiotic usage. Thus, to trail the hospital procedure, the patients are required to stay in hospitals for a longer duration, which is evidenced to be a key reason for hospital-acquired infections and intake of antibiotics.
Europe Antibiotics Market Report Highlights
- Based on drug class, the penicillin segment led the market with the largest revenue share of 25% in 2023, owing to its prominent application in treating various diseases, including diseases caused by streptococci, staphylococci, listeria, and clostridium. The cephalosporin segment is expected to grow at the fastest CAGR over the forecast period
- Based on type, the generic antibiotics segment held the market with the largest revenue share of 81.0% in 2023, attributed to the reasonability of generic inventions and a supportive regulatory framework
- Based on type, the branded antibiotics are anticipated to witness at the fastest CAGR over the forecast period, owing to the growing focus of key contributors to emphasize their product roles & distribution network
- Europe dominated the market and held a considerable share in the global antibiotics market owing to factors such as growing numbers of patients with various infections and continuous trials conducted by pharmaceutical businesses
- In September 2020, Shionogi & Co., Ltd. announced that it received FDA approval for a supplemental New Drug Application (sNDA), Fetroja (Cefiderocol). Antibiotics help treat hospital-acquired infectious pneumonia and ventilator-associated infective pneumonia
- In 2023, LifeArc, Medicines Discovery Catapult, and Innovate UK founded PACE (Pathways to Antimicrobial Clinical Efficiency) to fund and support researchers involved in drug and diagnostics development to tackle antimicrobial resistance (AMR)
Company Profiles
- AbbVie, Inc.
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Lupin Pharmaceuticals, Inc.
- Viatris, Inc.
- Melinta Therapeutics LLC
- Cipla, Inc.
- Shionogi & Co., Ltd.
- KYORIN Pharmaceutical Co., Ltd.
- GSK Plc
- Nabriva Therapeutics PLC
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 80 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $10.9 Billion |
| Forecasted Market Value (USD) by 2030 | $13.7 Billion |
| Compound Annual Growth Rate | 3.2% |
| Regions Covered | Europe |
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Europe Antibiotics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Europe Antibiotics Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis
Chapter 4. Europe Antibiotics Market: Drug Class Estimates & Trend Analysis
4.1. Technology Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Europe Antibiotics Market, by Drug Class Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.4.1. Cephalosporin
4.4.2. Penicillin
4.4.3. Fluoroquinolone
4.4.4. Macrolides
4.4.5. Carbapenems
4.4.6. Aminoglycosides
4.4.7. Sulfonamides
4.4.8. 7-ACA
Chapter 5. Europe Antibiotics Market: Type Estimates & Trend Analysis
5.1. Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Europe Antibiotics Market, by Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.4.1. Branded Antibiotics
5.4.2. Generic Antibiotics
Chapter 6. Europe Antibiotics Market: Action Mechanism Estimates & Trend Analysis
6.1. Action Mechanism Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Europe Antibiotics Market, by Action Mechanism Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.4.1. Cell Wall Synthesis Inhibitors
6.4.2. Protein Synthesis Inhibitors
6.4.3. DNA Synthesis Inhibitors
6.4.4. RNA Synthesis Inhibitors
6.4.5. Mycolic Acid Inhibitors
Chapter 7. Europe Antibiotics Market: County Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.4. Company Profiles
8.4.1. Company overview
8.4.2. Financial performance
8.4.3. Product benchmarking
8.4.4. Strategic initiatives
For more information about this report visit https://www.researchandmarkets.com/r/l6x4qo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
